- Previous Close
0.9700 - Open
0.9690 - Bid 0.9760 x --
- Ask 0.9830 x --
- Day's Range
0.9660 - 0.9890 - 52 Week Range
0.9430 - 1.7040 - Volume
98,527 - Avg. Volume
267,152 - Market Cap (intraday)
264.443M - Beta (5Y Monthly) 0.25
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date Apr 30, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.28
Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, medical innovations, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark. It prefers to be a lead investor in its portfolio companies however does consider co-investments also. It seeks to invest in up to five projects annually. Karolinska Development AB (publ) was founded in 2003 and is headquartered in Stockholm, Sweden.
www.karolinskadevelopment.comRecent News: KDEV.ST
View More
Performance Overview: KDEV.ST
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KDEV.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KDEV.ST
View MoreValuation Measures
Market Cap
262.55M
Enterprise Value
211.57M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
142.40
Price/Book (mrq)
0.21
Enterprise Value/Revenue
114.67
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-1.56%
Return on Equity (ttm)
-0.65%
Revenue (ttm)
1.84M
Net Income Avi to Common (ttm)
-8.1M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
42.01M
Total Debt/Equity (mrq)
0.17%
Levered Free Cash Flow (ttm)
-19.68M